The active drug in Bydureon BCise is exenatide in an extended-release form. Bydureon BCise is classified as a glucagon-like peptide-1 (GLP-1) agonist. Bydureon BCise isn’t currently available as a ...

If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...

Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...

The Food and Drug Administration (FDA) has expanded the approval of the Bydureon BCise (exenatide extended-release) injection to include patients 10 years of age and older with type 2 diabetes as an ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...

AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon. AstraZeneca says the European Commission has approved a new formulation of its ...

AstraZeneca PLCAZN announced that the European Commission has granted approval to Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of its GLP-1 receptor agonist ...

BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...